Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Conditions
Keywords
obesity hypoventilation syndrome, obstructive sleep apnea, bicarbonates, STOP-BANG
Brief summary
Obesity is a major risk factor for obstructive sleep apnea (OSA). However, OSA is still largely under diagnosed in patients with a high cardiovascular risk. In this population the STOP-BANG questionnaire facilitates OSA screening. Moreover, blood bicarbonate concentration is a simple tool to screen for chronic respiratory disease and if elevated, is a marker of cardiometabolic comorbidities in obese patients. A combination of blood bicarbonate concentration and STOP BANG score could provide a cost-effective method of screening for OSA in obese patients. Such screening could enable earlier management and might significantly reduce the costs of treatment and improve the quality of life of patients at 2 years.
Detailed description
OSA is a frequent condition in the general population (3% of women and 10% of men), but remains largely undiagnosed. Obesity is a risk factor for OSA. Sleep apnea is associated with diurnal and nocturnal symptoms (snoring, somnolence, fatigue), and with increased cardiometabolic morbidity and mortality. Currently, continuous positive airway pressure (CPAP) is the gold-standard treatment for OSA and the cost-effectiveness of this treatment has already been demonstrated. Easy-to-use procedures to identify OSA patients earlier and thus to initiate treatment earlier, need to be developed and validated. The STOP-BANG questionnaire has been designed to facilitate the screening of OSA patients. Moreover, a measure of blood bicarbonate concentration is a simple method for screening for chronic respiratory diseases and a marker of cardiometabolic comorbidities. A combination of blood bicarbonate measurement and STOP-BANG score could permit earlier screening and less expensive care of obese patients. The hypothesize is that such OSA screening in the obese population (bicarbonates + STOPBANG) associated with earlier care (with treatment if necessary) could lead to improvement in quality of life of obese patients at 2 years.
Interventions
OTHERCare pathway
Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
Sponsors
University Hospital, Angers
Poitiers University Hospital
Union hospital, Toulouse
Hospital Alpes Leman, Annemasse
Hospital La Louvière, Lille
Oriade Laboratory, Vizille
Cerballiance laboratories, Lille
Oriade laboratory, Annemasse
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Intervention model description
Open, controlled, randomized clinical trial (cluster randomization)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged from 18 to 80 years * Obese (BMI ≥ 30kg/m²) * Referred by GPs to the medical analysis laboratory for usual biological assessment * Patients with no respiratory follow-up already in place * Patient affiliated with a social protection plan * Bicarbonate - Concentration ≥ 27 mmol/L * STOP-BANG score ≥ 3 * Informed written consent signed by the patient
Exclusion criteria
* Acute disease or recently diagnosed chronic disease (\< 2 months) * Hospitalization for respiratory, metabolic or cardiovascular event (\< 2 months) * Renal insufficiency stage 4 or 5, or autoimmune disease, or viral hepatitis, or cirrhosis * Cited persons in Sections L1121-5 to L1121-8 of the CSP (pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, a person who is the subject of a judicial or administrative legal protection) * Patients already included in an interventional study (end of the study \< 1 month)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year medico-economic impact of the implementation of early care in obese patients with OSA | 24 months | incremental cost-effectiveness ratio at 24 months calculated from the difference in healthcare costs between the 2 groups (early care vs usual care) adjusted to the difference in the number of quality adjusted life years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact on laboratory test results (troponin) at 12 months | 12 months | troponin |
| Impact on laboratory test results (troponin) at 24 months | 24 months | troponin |
| Impact on laboratory test results (NT-proBNP) at 12 months | 12 months | NT-proBNP |
| Impact on laboratory test results (NT-proBNP) at 24 months | 24 months | NT-proBNP |
| Impact on laboratory test results on cholesterol at 12 months | 12 months | cholesterol |
| Impact on laboratory test results on cholesterol at 24 months | 24 months | cholesterol |
| Impact on laboratory test results on triglycerides at 12 months | 12 months | triglycerides |
| Economic impact of the implementation of early care in obese patients with OSA over 3 years on the healthcare costs | 3 years | The economic impact on healthcare costs from the Health Insurer's perspective will be calculated from the difference in healthcare costs between the two groups (early care vs usual care) |
| To evaluate the sensitivity of the screening tool | 24 months | The sensitivity will be evaluated by comparison with polysomnography |
| To evaluate the specificity of the screening tool | 24 months | The specificity will be evaluated by comparison with polysomnography |
| To evaluate the negative Predictive Value | 24 months | The negative predictive value will be evaluated by comparison with polysomnography |
| To evaluate the positive predictive value of the screening tool | 24 months | The positive predictive value will be evaluated by comparison with polysomnography |
| Clinical impact of the early care pathway on blood pressure at 12 months | 12 months | Blood pressure at home |
| Clinical impact of the early care pathway on blood pressure at 24 months | 24 months | Blood pressure at home |
| Clinical impact of the early care pathway on quality of life at 12 months | 12 months | The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status. 0 means the worst health status. |
| Clinical impact of the early care pathway on quality of life at 24 months | 24 months | The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status. 0 means the worst health status. |
| Impact on laboratory test results on triglycerides at 24 months | 24 months | triglycerides |
| Clinical impact of the early care pathway (early care) on quality of life at 24 months | 24 months | Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life. This scale is numbered from 0 to 4. higher values represent a worse outcome |
| Clinical impact of the early care pathway on pharmacological treatments at 12 months | 12 months | number of pharmacological treatments |
| Clinical impact of the early care pathway on pharmacological treatments at 24 months | 24 months | number of pharmacological treatments |
| Impact on laboratory test results on glycaemia at 12 months | 12 months | glycaemia |
| Impact on laboratory test results on glycaemia at 24 months | 24 months | glycaemia |
| Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 12 months | 12 months | Homeostasis model assessment (HOMA)-index |
| Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 24 months | 24 months | Homeostasis model assessment (HOMA)-index |
| Impact on laboratory test results on hepatic transaminases at 12 months | 12 months | transaminases (ASAT, ALAT) |
| Impact on laboratory test results on hepatic transaminases at 24 months | 24 months | transaminases (ASAT, ALAT) |
| Impact on laboratory test results on creatinine at 12 months | 12 months | creatinine |
| Impact on laboratory test results on creatinine at 24 months | 24 months | creatinine |
| Impact on laboratory test results on C-Reactive Protein (CRP) at 12 months | 12 months | C-Reactive Protein (CRP) |
| Impact on laboratory test results on C-Reactive Protein (CRP) at 24 months | 24 months | C-Reactive Protein (CRP) |
| Impact on laboratory test results on alpha2-macroglobulin at 12 months | 12 months | alpha2-macroglobulin |
| Impact on laboratory test results on alpha2-macroglobulin at 24 months | 24 months | alpha2-macroglobulin |
| Clinical impact of the early care pathway (early care) on quality of life at 12 months | 12 months | Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life. This scale is numbered from 0 to 4. higher values represent a worse outcome |
Countries
France
Outcome results
None listed